Ji, Linong
Liu, Jie
Xu, Zhi Jin http://orcid.org/0000-0002-5916-1605
Wei, Zhiqi
Zhang, Ruya
Malkani, Seema
Cater, Nilo B. http://orcid.org/0000-0001-5868-8643
Frederich, Robert http://orcid.org/0000-0002-5175-3112
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin
https://doi.org/10.2337/db18-1140-p
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
https://doi.org/10.1186/s12933-019-0856-7
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
https://doi.org/10.1007/s13300-022-01345-6
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Documents that mention this clinical trial
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
https://doi.org/10.1007/s13300-022-01345-6
Funding for this research was provided by:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Pfizer Inc., New York, NY, USA
Article History
Received: 13 October 2022
Accepted: 11 November 2022
First Online: 3 February 2023